Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gait

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    138 result(s) found for: Gait. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2009-012643-42 Sponsor Protocol Number: 28119 Start Date*: 2010-01-06
    Sponsor Name:University Medical Center Groningen
    Full Title: Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option
    Medical condition: Parkinson's disease, in particular the symptom Freezing of Gait
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004685-17 Sponsor Protocol Number: ERA2005neuro Start Date*: 2005-11-16
    Sponsor Name:CUB - Hôpital Erasme
    Full Title: A prospective placebo controlled study of botulilium toxin (BOTOX) on gait disorder induced by spastic equinovarus foot.
    Medical condition: Spastic equinus foot is a common dynamic deformity in patients with cerebral palsy. This dynamic deformity, mainly caused by spasticity of the soleus, gastrocnemius and tibialis posterior muscles, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018226-29 Sponsor Protocol Number: botox2010 Start Date*: 2010-04-20
    Sponsor Name:
    Full Title: The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with a stiff knee gait.
    Medical condition: Stroke patients with stiff knee gait. Stiff knee gait is characterized as a diminished knee flexion during swing phase of gait. It is common in stroke patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000403-32 Sponsor Protocol Number: LIDrfvm001 Start Date*: 2019-07-23
    Sponsor Name:Roessingh Research and Development
    Full Title: The effect of lidocaïne injections in the m. vastus intermedius and the m. rectus femoris on the gait pattern in patients walking with stiff knee gait after a stroke.
    Medical condition: Patients walking with stiff knee gait after a stroke
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003184-11 Sponsor Protocol Number: R0002820 Start Date*: 2016-01-04
    Sponsor Name:Radboud University Medical Centre
    Full Title: Functional effects of botulinum toxin in the hip adductors and subsequent exercise in patients with hereditary spastic paraplegia: a pilot RCT
    Medical condition: Hereditary Spastic Paraplegia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001218-40 Sponsor Protocol Number: SC12-02 Start Date*: 2012-05-21
    Sponsor Name:FONDAZIONE SANTA LUCIA
    Full Title: EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTS
    Medical condition: Patients suffering for Idiopathic Parkinson’s Disease. H&Y stage > or = 2 with un-satisfactory control by on-going pharmacological therapy (Levodopa, COMT & MAO-inhibitors), characterised by an in...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10056242 Parkinsonian gait PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000788-30 Sponsor Protocol Number: 1.2022 Start Date*: 2023-04-13
    Sponsor Name:Uzdrowisko Kamień Pomorski S.A.
    Full Title: Evaluation of the effectiveness of Methocarbamol in the treatment of spasticity in people with spinal cord injury.
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004474-42 Sponsor Protocol Number: V3_06082015 Start Date*: 2015-05-07
    Sponsor Name:Copenhagen University Hospital at Hvidovre
    Full Title: Treatment of equinus gait caused by dynamic tightening of the calf muscles in children with cerebral palsy. A randomized, placebo controlled Botulinum toxin type A volume/response study.
    Medical condition: Treatment of equinus gait caused by dynamic tightening of the calf muscles in children with cerebral palsy.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10015112 Equinus deformity of foot, acquired LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003482-25 Sponsor Protocol Number: CBYM338E2202 Start Date*: 2015-01-30
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 28 week, randomized, double-blind, placebo-controlled, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal mu...
    Medical condition: sarcopenia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10063024 Sarcopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DK (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-005653-24 Sponsor Protocol Number: IRB00003099 Start Date*: 2021-06-28
    Sponsor Name:Clínica Integral del pie-Ana Sans
    Full Title: Effectiveness of botulinum toxin infiltration in spasticity of the 1st toe in patients with neurological pathology
    Medical condition: The application of Botox is described in the technical sheet for spasticity and has already been applied to the foot. This is how we speak of a phase IV clinical trial, with a low level of interven...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005076-34 Sponsor Protocol Number: BEL-FMP-12-10325 Start Date*: 2013-01-03
    Sponsor Name:Cliniques Universitaires Saint-Luc, Neurologie
    Full Title: Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005312-26 Sponsor Protocol Number: FACEG Start Date*: 2013-03-18
    Sponsor Name:Hospital of the University of Munich, Grosshadern
    Full Title: Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder
    Medical condition: cerebellar gait disorder, cerebellar ataxia, sensorimotor adaption and ocular motor disorders, postural sway, dysarthria
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10008025 Cerebellar ataxia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004892-11 Sponsor Protocol Number: SteP-on Start Date*: 2021-04-22
    Sponsor Name:OSPEDALE SANTA MARIA DELLA MISERICORDIA
    Full Title: A randomized, double-blind, placebo controlled, multicentre study to evaluate the effect of safinamide on freezing of gait (FOG) in mid- to late-stage fluctuating PD patients
    Medical condition: • Subjects of both genders over 18 years of age, with a clinical diagnosis of idiopathic PD • A Modified Hoehn and Yahr stage of = 4 in the “off” state; • A stable (4 weeks since last modification)...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005874-11 Sponsor Protocol Number: 0822-035 Start Date*: 2009-02-24
    Sponsor Name:Laboratoires Merck Sharp & Dhome-Chibret
    Full Title: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of ...
    Medical condition: This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031283 Osteoporosis fracture LLT
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000471-27 Sponsor Protocol Number: CBYM338E2202E1 Start Date*: 2015-10-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 28 week randomized withdrawal extension of a doubleblind, placebo-controlled, parallel group study to assess durability of effect on skeletal muscle strength and function upon withdrawal of bimag...
    Medical condition: Sarcopenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10063024 Sarcopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001696-79 Sponsor Protocol Number: KH176-201 Start Date*: 2016-09-06
    Sponsor Name:Khondrion BV
    Full Title: A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitoc...
    Medical condition: Inherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005197-78 Sponsor Protocol Number: 1 Start Date*: Information not available in EudraCT
    Sponsor Name:Queen's Medical Centre, Nottingham, University Hospital NHS Trust,
    Full Title: A multi-centre, randomised, parallel group, cross-over study comparing the efficacy and safety of double versus multiple injections of Botulinum Toxin type-A (Dysport®), into the gastrocnemius musc...
    Medical condition: Spasticity of the Gastrocnemius Muscle due to Cerebral Palsy
    Disease: Version SOC Term Classification Code Term Level
    8.0 10024132 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002896-17 Sponsor Protocol Number: V1.17.05.2013 Start Date*: Information not available in EudraCT
    Sponsor Name:Orthopädisches Spital Speising
    Full Title: Functional evaluation of two therapy concepts: dynamic orthoses and BoNT
    Medical condition: Infantile cerebral palsy
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000460-34 Sponsor Protocol Number: ALCAT Start Date*: 2015-11-18
    Sponsor Name:Hospital of the University of Munich
    Full Title: Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT)
    Medical condition: Cerebellar ataxia is a form of ataxia originating in the cerebellum and is most often caused by neurodegenerative disorders of the cerebellum, either hereditary or sporadic. The leading clinical sy...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-003016-87 Sponsor Protocol Number: C3651003 Start Date*: 2023-03-13
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF G...
    Medical condition: Cachexia, a loss of weight due to the catabolism of muscle and fat tissue. The progressive worsening of cachexia impacts a cancer patient’s quality of life and contributes to poor survival.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) HU (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:01:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA